In the earnings, more than the numbers the management comments on the Qualcomm lawsuit were awaited. Though there was nothing new, the management expressed its confidence of success stating that “none of the prior art cited by Qualcomm contemplates our invention and look forward to proving this in court”. Stocks of the companies involved in patent infringement lawsuits move with the news flow related to the progress of the trial. Parkervision's fate is very much dependent on this one lawsuit. There are several other companies like this. PLC Systems (PLCSF), a medical device company sold its product laser heart in 2011 to concentrate on a singel, more potential product (RenalGuard) for which it was later able to obtain several U.S and European patents. Parkervision has already rewarded the investors with good returns over the last one year. More strength has developed after the Markman order in February when the court adopted 90% of its definitions for disputed terms and adopted none of those proposed by Qualcomm. The earnings for Q1'13 were not good with the net loss increasing by nearly 60% to $6.5 million ($4.1 million in Q1'12). This increased the loss per share to $0.08 ($0.06 in Q1'12). The main component of the increase was the non cash share based compensation ($1.4 million) and legal fees related to the litigation ($0.9 million). The company had cash and available for sale securities of $17.8 million as on March 31. In Q1'13, the company used $5 million cash compared with $3.4 million used in the same quarter a year ago. These numbers may put some pressure on the price but one has to keep in mind that the stock movement is linked more to the events in the lawsuit. So far the events have been in favor of the company, and so the stock may continue to rise after a correction. However, any negative news can lead to a strong dip.